Treats mild to moderate infections (unless otherwise indicated) caused by susceptible…. ANDA 91656, held by Cadila Pharms Ltd. Ofloxacin.
As of Nov 16, 2026, ANDA 91656 (Ofloxacin), held by Cadila Pharms Ltd, was first approved by FDA on Sep 18, 2014, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 18, 2014 | Original application | Approved | None posted |
| Oct 16, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 18, 2018 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jul 26, 2016 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 18, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters